Neurons have evolved strategies to evade immune surveillance that include an inability to synthesize the heavy chain of the class I major histocompatibility complex (MHC), proteins that are necessary for cytotoxic T lymphocyte (CTL) recognition of target cells. Multiple viruses have taken advantage of the lack of CTL-mediated recognition and killing of neurons by establishing persistent neuronal infections and thereby escaping attack by antiviral CTL. We have expressed a class I MHC molecule (D b) in neurons oftransgenic mice using the neuron-specific enolase (NSE) promoter to determine the pathogenic consequences of CTL recognition ofvirally infected, MHC-expressing central nervous system (CNS) neurons. The NSE-D b transgene was expressed in H-2 b founder mice, and transgene-derived messenger RNA was detected by reverse transcriptase-polymerase chain reaction in transgenic brains from several lines. Purified primary neurons from transgenic but not from nontransgenic mice adhered to coverslips coated with a conformation-dependent monoclonal antibody directed against the D b molecule and presented viral peptide to CTL in an MHC-restricted manner, indicating that the D b molecule was expressed on transgenic neurons in a functional form. Transgenic mice infected with the neurotropic lymphocytic choriomeningitis virus (LCMV) and given anti-LCMV, MHC-restricted CTL displayed a high morbidity and mortality when compared with controls receiving MHC-mismatched CTL or expressing alternative transgenes, After CTL transfer, transgenic brains showed an increased nutnber of CD8 + cells compared with nontransgenic controls as well as an increased rate of clearance of infectious virus from the CNS. Additionally, an increase in blood-brain barrier permeability was detected during viral clearance in NSE-D b transgenic mice and lasted several months after clearance of virus from neurons. In contrast, LCMV-infected, nontransgenic littermates and mice expressing other gene products from the NSE promoter showed no CNS disease, no increased intraparenchymal CTL, and no bloodbrain barrier damage after the adoptive transfer of antiviral CTL. Our study indicates that viral infections and CTL-CNS interactions may induce blood-brain barrier disruptions and neurologic disease by a "hit-and-run" mechanism, triggering a cascade of pathogenic events that proceeds in the absence of continual viral stimulation.
S
everal properties unique to the central nervous system (CNS) 1 led to the concept that the CNS is an immuneprivileged site (1, 2) . To recognize and lyse target cells within the brain parenchyma, immune effector cells must cross the blood-brain barrier, a tightly packed wall of endothelia that separates the circulatory system from CNS cells. While nutrients and oxygen either diffuse or are transported across the barrier, the passage of blood-borne Abbreviations used in this paper: aa, amino acid; CNS, central nervous system; LCMV, lymphocytic choriomeningitis virus; mRNA, messenger 1KNA; NP, nucleoprotein; NSE, neuron-specific enolase.
proteins and cells (including red blood cells and resting lymphocytes) into the brain is restricted, because of both the fight junctions between the capillary endothelia and a lack of active cell transport by the endothelial cells themselves (for review see references 3 and 4). However, the barrier does not isolate the parenchyma from activated immune cells; activated T lymphocytes and monocyte/macrophages traverse the intact blood-brain barrier and traffic through the brain (5) (6) (7) (8) (9) . These infiltrating, activated T cells are restricted from recognizing CNS targets, however, at least partly because of a paucity of cell surface molecules required for T cell-target interaction. Resident cells of the CNS normally express low to undetectable levels of both class I and II MHC molecules (10) (11) (12) . The class I MHC glycoproteins present foreign (viral) proteins in the form of 8-11 amino acid (aa) peptides to the T cell receptor of CD8 + cytotoxic T lymphocytes. Neurons, both in vivo (13) (14) (15) and in vitro (12, 14, (16) (17) (18) , do not express MHC class I molecules and, hence, do not serve as targets for CTL-mediated lysis. Multiple RNA and DNA viruses, including members of the Herpes-, Paramyxo-, Rhabdo-, Picoma-, and Arenavirus families, infect neurons of the CNS (for review see references [19] [20] [21] . Viruses from each of these families are able to establish latent or persistent infections in CNS neurons, most likely because viral persistence in neurons through immune evasion is preferable to lysis by antiviral CTL of these essential and irreplaceable cells.
Earlier studies began to characterize neuron-virus-CTL interactions using the OBL-21 neuronal cell line (14) . These cells contain neurofilaments and show electrophysiologic responses consistent with neurons (22) , although, unlike CNS neurons, they are dividing cells. Like neurons in vivo, OBL-21 cells fail to express MHC molecules, and, although infected with virus and expressing viral proteins on their surfaces, were not lysed by antiviral CTL (14) . However, after complementation of class I MHC antigenpresenting capacity by transfection with a Db-encoding retroviral vector, infected OBL-21 cells were lysed by antiviral CTL (14) .
In this paper we extend these in vitro observations in vivo. First, transgenic mice that express a class I MHC molecule on CNS neurons were established. Second, MHCexpressing neurons purified from such transgenic mice were susceptible to lysis by virus-specific MHC-restricted CTL, whereas neurons from nontransgenic mice were not. CNS disease was induced in virally infected transgenic mice after adoptive transfer of virus-specific, MHC-restricted CTL. The disease lasted for several months after CTL transfer and was associated with an increased number ofintraparenchymal CD8 + cells and a chronic destabilization of the blood-brain barrier.
Materials and Methods
Animals, Cells, and Viruses. C57BL/6 (H-2b), SJL (H-29, and BALB/cByJ (H-2 a) inbred mice were obtained from the closed breeding facility of The Scripps Research Institute (La JoUa, CA). Animals were maintained in conditions consistent with American Association for the Accreditation of Laboratory Animal Care regulations throughout the course of the investigation. Lymphocytic choriomeningitis virus (LCMV) strain Armstrong CA 1371 clone 53b (LCMV ARM) was used in these studies. The origin, cloning and plaque purification of stock virus have been reported (23, 24) . Virus was grown in baby hamster kidney cells and was plaque purified and titered on Vero cell monolayers as described (24) . BALB clone 7 (H-2 a) fibroblasts and Vero cells were grown in MEM supplemented with 10% heat-inactivated FCS, 1 mM r-glutamine, 104 U/ml penicillin, and 10 mg/ml streptomycin. MC57 (H-2 b) fibroblasts were cultured in RPMI 1640 with the supplements listed above. CTL clones restricted by H-2 b (clone NP18 recognizing nucleoprotein [NP] aa residues 396-404; 25) and H-2 a (clone HD8 recognizing NP aa residues 118-127; 26) were used. These clones were mainrained in culture as described (25) .
Persistent infection of mice was achieved by inoculation of 1,000 PFU of LCMV ARM intracerebrally into newborn mice within 18 h of birth. Such mice carry infectious virus and viral nucleic acid in many cells, including neurons, throughout their lives (27) .
Cloning Procedures and Establishment of Transgenic
Mice. Standard molecular techniques (28, 29) were used for the construction of the NSE-D b transgene. The NSE expression vector (30, 31) was obtained from S. Forss-Petter, (The Scripps Research Institute) and the Mo/D b clone (32) from R. Flavell, (Yale University, New Haven, CT). Promoter-transgene junctions created by the subcloning were sequenced before microinjection. Fertilized oocytes were obtained from (C57B1/6 • SJL) female mice. Purification of the transgene, preparation of mice, microinjection, and embryo implantations were carried out as described (33) (34) (35) .
Transgenic mice were identified by tail biopsy and subsequent DNA isolation. 10 FLg of DNA was slot blotted onto filters (Nytran; Schleicher & Schuell, Inc., Keene, NH) and probed with the SV40 sequence located at the 3' end of the NSE expression cassette.
Reverse Transcriptase-PCR (RT-PCR).
Brains and other organs were removed from saline-perfused mice and were snap frozen in liquid nitrogen. The tissues were stored at -70~ before homogenization. Tissues were homogenized using a Virtishear (Virtis Co., Inc., Gardiner, NY) for 30 s in 1 ml Tri-reagent/100 mg tissue (Molecular Research Center, Inc., Cincinnati, OH), and RNA was purified according to their recommended protocol. 500 ng of total RNA was reverse transcribed by the random priming method, using random hexamers (Pharmacia Biotech, Inc., Piscataway, NJ) and reverse transcriptase (GIBCO BRL, Gaithersburg, MD). The RNA-cDNA duplex was then subjected to 40 rounds of PCR (60~ annealing temperature; Taq I polymerase from GIBCO BRL), using 20-mer oligonucleotide primers designed to amplify transgene specific sequences: A = 5' GAGAT CGACT CTAGA GGATC 3'; B = 5' GCGCT CTGGT TGTAG TAGCC 3'. The PCR products were visualized by ethidium bromide intercalation on a 1% agarose gel.
Hippocampal Neuron Cultures and Protein Detection. Embryonic mice (day [16] [17] [18] were used for the preparation of dissociated hippocampal neuron cultures following the protocol of Banker and Goslin (36) with minor modifications (37; Rall, G. F., unpublished results). Briefly, hippocampi were dissected from embryos and placed in ice-cold plating medium (DMEM supplemented with 10% fetal bovine serum, 104 U/ml penicillin, and 10 mg/ml streptomycin). The tissues were washed three times with ice-cold PBS and digested with trypsin-EDTA (Sigma Chemical Co., St. Louis, MO) at 37~ for 15 rain. The tissue was washed twice with plating medium, mechanically dissociated with firepolished pipettes, and passed through a cell strainer (Falcon Labware, Oxnard, CA) to obtain a single-cell suspension. The neurons were spun at 150 g for 7 rain onto a serum cushion, resuspended, counted, and plated onto either poly-L-lysine (Sigma Chemical Co.) or antibody-coated, acid-washed, round glass coverslips (Carolina Biological Supply Co., Burlington, NC) at a density of 500 cells/mm 2.
Individual coverslips were incubated with affinity-purified goat anti-mouse IgG (Cappel Laboratories, Cochranville, PA; 10 p~g/ slip) for 4 h, washed with PBS and then coated with rnAbs specific for either the D b class I MHC molecule (B22. 249.R1, 1:500; Cedarlane Laboratories Ltd., Homby, Ontario, Canada) or to the L a class I MHC molecule (30-5-7S, 1:500; Cedarlane Laborato-ries Ltd.) in doses of 3 Fg/coverslip (38, 39) . Coverslips were placed in a humidified incubator overnight, and, immediately before neuron plating, the antibody was aspirated and the slips were washed once with PBS, pH 7.4. 4 h after the neurons were added to the coverslips, the slips were placed on top of a confluent primary astrocyte feeder layer (40) , in serum-free neurobasal medium (GIBCO BRL) supplemented with growth factors (B27 additive; GIBCO BRL). The cells were maintained at 37~ in 5% CO2.
In Vitro Killing Assay. Neurons cultured in vitro for 48 h were either untreated or were coated with peptides representing LCMV CTL epitopes restricted by either H-2 b (NP aa 396-404: NH2-FQPQNGQFI-COOH) or H-2 d (NP aa 118-127: NH2-SERPQASGVG-COOH) at a concentration of 40 beg/2 • 104 targets 1 h before the addition of CTL. H-2 b-or H-2a-restricted CTL clones were then added to the cultures at a 1:1 ratio, and they were allowed to incubate for 6 h. After removal of the clones and debris by successive PBS washes, the neurons were fixed with 2% paraformaldehyde and were counterstained with hematoxylin. 10 random fields were counted per slide, and the results were confirmed in three independent experiments. MC57 (H-2 b) and BALB c17 (H-2 a) fibroblasts served as controls.
Adoptive Transfer of Memory CTL into Persistently Infected
Mice. Adoptive transfer of antiviral CTL into persistently infected mice has been described (41) . The memory cytotoxic effector cells transferred were obtained from normal adult C57BI/6 or SJL mice infected 60-120 d earlier by intraperitoneal inoculation of 2 X 10 s PFU of LCMV. Spleens were removed and dissociated, and a single-cell suspension was prepared and cultured in 24-well plates with syngeneic LCMV-infected and irradiated peritoneal macrophages (as stimulators) and syngeneic irradiated spleen ceils (as feeder cells). Adherent lymphocytes (secondaries) were expanded three times on infected, irradiated stimulator cells before transfer into age-matched (6-13-wk-old) persistently infected mice and nontransgenic controls. Transgenic and nontransgenic mice (H-2 b) were bred with nontransgenic SJL mice (H-2 s) to generate H-2 bxs mice for the adoptive transfer experiments. The progeny of such breedings was infected with LCMV (103 PFU) within 24 h of birth to establish persistent infections. The presence of virus in these mice (between 4 and 8 wk) was determined before the adoptive transfer by serum plaque assay. 24 h before the transfer of 5 X 106 secondary CTL intraperitoneally, mice were irradiated with 400 rad to accommodate the adoptively transferred cells. The health of the animals was monitored daily from 1 to 30 d after adoptive transfer and weekly thereafter, and evaluated on a four-level scale: 1, healthy and indistinguishable from uninfected normal mice; 2, fur slightly ruffled, posture hunched, eyes partially closed, reduced mobility; 3, ruffled, hunched, and tremulous, eyes mucous filled and closed, significant motor impairment; 4, dead.
Viral titers in serum were monitored 6, 15, 60, and 120 d after adoptive transfer, and mice from experimental and control groups were killed at 15 and 60 d after adoptive transfer for histological studies.
Detection of CD8 + Lymphocytes within Brain Sections. /Mice were
deeply anesthetized with a 3.8% solution of chloral hydrate and were perfused with normal saline. Brains were rapidly removed, quick frozen in a dry ice/isopentane bath, and stored at -70~ 10-1am horizontal sections were cut and fixed in 95% ethanol for 15 min at -20~
were blocked with avidin-biotin (Vector Laboratories, Inc., Burlingame, CA), and were incubated for 1.5 h with mAbs to the murine CD8 molecule (CD8a and Ly3, diluted 1:50; Pharmingen, San Diego, CA). After washing, sections were incubated with biotinylated secondary antibodies, followed by an avidin-biotin reaction (ABC Elite; Vector Laboratories, Inc.) and a color reaction using diaminobenzidene and hydrogen peroxide. Sections were lightly counterstained with hematoxylin and were mounted with Aquamount (Lemer Laboratories, New Haven, CT).
The median values of the number of CD8 + lymphocytes per brain section within a given group were calculated. At least four horizontal sections were evaluated per mouse brain.
Blood-Brain Barrier Permeability. Mice were deeply anesthetized with a 3.8% solution of chloral hydrate. 2 ml of a 2% Evans blue solution in PBS was infused transcardially over a l-rain period. 3 rain later, mice were perfused with 4% paraformaldehyde in PBS, and brains were removed and stored in 0.2% paraformaldehyde in PBS.
Results
The (40) was cloned into the BamHI restriction site within exon 2 of the NSE cassette ( Fig. 1) , and the resulting plasmid was characterized by restriction analysis and sequencing of promoter-transgene junctions. The linearized, gel-purified NSE-D b transgene was then microinjected into ~200 (C57B1/6 • SJL)F2 one-cell stage embryos.
From this microinjection, 42 mice were born, 12 of which contained the transgene. Five of these founder mice were selected for breeding and were back-crossed onto the C57B1/6 background. After three back-crosses, the CTL response within these mice was completely restricted to the H-2 b haplotype as determined by chromium release assays (data not shown).
Tissue expression of the NSE-D b messenger RNA (mRNA) was analyzed by RT-PCR on RNA isolated from transgenic and nontransgenic mouse tissues (brain, Brains were removed from transgenic (+) and nontransgenic (-) mice. Total RNA was extracted and subjected to RT-PCR as described in Materials and Methods, Primers A and B were used to amplify transgene-specific mRNA. The primer pair was designed to differentiate spliced and unspliced templates by size; the primers span intron 1 of the D b sequence, so that the predicted PCR product derived from spliced mRNA is 180 bp smaller than the product derived from either unspliced RNA or residual DNA in the preparation (Fig. 2 13) . Spliced mRNA (as a 320-bp PCR product) was detected in each of the five transgenic lines, and, in some cases, a PCR product corresponding to DNA or unspliced RNA (500 bp) was seen (lines 23 and 29) . No PCR product was amphfied in nontransgenic mice (line 21-). Results obtained in three mice per group are shown.
spleen, kidney, pancreas, liver, testes, gut, thymus, lung, heart, and optic and sciatic nerves). Total brain R N A isolated from mice of six transgenic lines (7, 9, 11, 21, 23 , and 29) contained transgene-derived m R N A , whereas brain R N A from nontransgenic littermates did not (Fig. 2 A) . Transgenic lines 9 (data not shown) and 11 were used for subsequent experiments. N o spliced NSE-D b m R N A was detected in other organs except for in the testes of line 29 (data not shown). Line 29 was not used for further experiments. Total R N A purified from primary astrocyte/microglial cultures derived from transgenic neonatal mice of lines 9 and 11 were also analyzed by the R T -P C R approach. N o R N A P C R product corresponding to the NSE-D b transgene was detected in these cultures (data not shown).
The NSE-D b expression at the protein level was too low to be detected by immunostaining of tissue sections. H o wever, neuronal expression of D b protein was demonstrated by culturing primary embryonic hippocampal neurons and testing their ability to grow on glass coverslips coated with an mAb specific for either D b or for a heterologous M H C molecule (anti-Ld). Neurons from transgenic (Db-expressing) mice adhered to anti-D b-, but not to anti-L&coated coverslips (Fig. 3) . Nontransgenic neurons did not attach to either type o f coverslip, confirming the absence o f M H C class I on their surface. Notably, the antibody used, B.22.249, is conformation dependent (32) . Therefore, the D b molecule is expressed in a conformationally correct form on the surface oftransgenic neurons.
The Transgene-derived D b Molecule Conferred CTL Recognition and Lysability to CNS Neurons In Vitro. W e next determined whether transgenic neurons could present antigen and serve as targets for CTL-mediated lysis in a neuronal survival assay. Primary neurons do not take up S~Cr; therefore, instead o f standard chromium release assays, an alternative assay was used. Transgenic and nontransgenic neurons were incubated with peptides encoding LCMV-specific epitopes that are restricted by either H-2 b or H-2 d (25, 26, 35) . Peptide-coated neurons were reacted with specific anti-LCMV H-2 b-or H-2&restricted CTL clones, and the number of viable neurons was determined after a 6-h incubation. Db-expressing neurons incubated with H-2 brestricted viral peptide and a matched CTL clone showed a significant reduction (73%) in cell viability (P < 0.05), whereas nontransgenic neurons did not (Fig. 4) . These data were reproducible in three independent experiments.
Persistently Infected, Transgenic Mice Developed CNS Disease after Adoptive Transfer of LCMV-specific Db-restricted CTL.
NSE-Db-expressing mice were maintained in a specific pathogen-free facility. N o differences in appearance, fecundity, or life span were noted between uninfected transgenic animals and nontransgenic littermate controls (data not shown).
To determine the antigen-presenting capacity of transgenic neurons in vivo and the consequences of their interaction with Db-restricted CTL, mice were infected as neonates with LCMV. In this persistent infection, most tissues, including the CNS, liver, spleen, and kidney, contain LCMV; within the CNS, the neuron is the only cell type infected (42, 43) . Adoptive transfer of virus-specific, MHC-restricted CTL (41, 44) results in CTL-mediated clearance of LCMV from all sites, other than neurons and renal glomeruli, within 10-30 d after transfer. The eventual elimination of virus and viral nucleic acid from neurons occurs over a longer period (60-120 d after adoptive transfer) and does not involve obvious infiltration of the brain parenchyma (41) . The mechanism of viral clearance from nontransgenic, persistently infected brains is not completely understood, but does not seem to occur via classical C T Ltarget cell interactions.
NSE-D b transgenic mice, NSE-amyloid precursor protein (APP) transgenic mice (expressing APP as a n o n -M H C transgenic control; 31), and nontransgenic littermates were infected with LCMV at birth. Each of these groups of mice was generated by breeding an H-2 b transgenic parent with a nontransgenic SJL (H-29 mouse, resulting in H-2 bX~ offspring. Secondary immune T lymphocytes raised in H-2 b or H-2 ~ mice were then adoptively transferred into the persistently infected H-2 bx~ animals. This experiment was based on the following rationale: both H- (Fig. 5) .
Animal health was monitored daily and independently by at least two investigators after adoptive transfer o f CTL. The genetic profile o f the mice and the CTL that they received were unknown to the observers to avoid bias. Persistently infected mice appeared healthy before the adoptive transfer. 5-15 d after transfer, when CTL are killing virally infected MHC-expressing cells in peripheral tissues (liver, spleen, kidney, etc.) (41), some mice showed mild to moderate illness (clinical levels 2-3) in all experimental groups. The combined results (Table 1) of three independent adoptive transfer experiments using a minimum o f four mice per experimental group revealed the following: (a) N S E -D b transgenic mice exposed to H-2 b CTL showed significantly higher morbidity and mortality than NSE-APP or nontransgenic controls receiving similar immunotherapy; (b) NSE-D b mice had a higher morbidity and mortality when given H-2 b CTL compared with H-2 + CTL, whereas H-2 b and H-2 s CTL had a similar effect in the control groups; and (c) NSE-D b mice that survived the initial 15-d viral clearance period remained sick throughout the observation period (clinical stages 2-3), whereas control mice returned to clinical stage 1 after viral clearance.
NSE-lY' Transgenic Mice Receiving Adoptive CTL Therapy Showed Increased Numbers of CD8 + Lymphocytes in the CNS
Parenchyma and Accelerated Viral Clearance. Brains were removed from mice at various time points after adoptive transfer and stained with mAbs to murine CD8 to compare the number of infiltrating CTL within the brains of NSE-D b transgenic versus control mice. Photomicrographs of representative routine brains are shown in Fig. 6 , and a quantitative summary is shown in Table 2 . Uninfected NSE-D b transgenic brains contained rare CTL (Fig. 6 A; Table 2 , group A), suggesting that the expression of D b on neurons per se is not sufficient to recruit T cells into the parenchyma. The CD8 § CTL found within the brains o f persistently infected mice were distributed uniformly throughout the parenchyma, and both transgenic and nontransgenic mice killed at various ages after neonatal L C M V infection contained similar numbers of intraparenchymal CD8 § T cells (Fig. 6 B; Table 2 (Fig. 7) . Notably, despite an accelerated viral clearance, transgenic mice remained sick for up to 120 d after the adoptive transfer. would be associated with an alteration of the blood-brain barrier, mice were injected with Evans blue, a dye which binds to serum proteins and is excluded from the brain parenchyma by the normal blood-brain barrier. In persistently infected NSE-D b transgenic mice, leakage of the dye into the brain parenchyma was observed as early as 15 d (n = 4) (data not shown) and as late as 120 d (n = 5) after adoptive transfer of H-2 b restricted CTL ( Fig. 8 ; Table 3 ). These results indicate a prolonged abnormal permeability of the blood-brain barrier, which persisted in the absence of viral antigen. Subtle differences in the pattern of permeability changes could be related to variations in the distribution or activity of the infiltrating lymphocytes. By contrast, no other group of mice, including transiently sick nontransgenic mice killed 9 d after CTL administration, showed any abnormality in the permeability of the blood-brain barrier (Table 3 ; Fig. 8 ).
The Increased Sickness of N S E -D b Transgenic Mice Correlated with a Chronic

Discussion
The current study revealed a number of novel findings. The expression of class I MHC glycoproteins in neurons of NSE-D b transgenic mice had no deleterious effects on the health, fecundity, or life span of uninfected mice. MHC class [-expressing hippocampal neurons of transgenic mice presented exogenous viral peptide to H-2-matched CTL in vitro, resulting in neuronal lysis. In vivo interactions of antiviral H-2b-restricted CTL with Db-expressing neurons in mice persistently infected with LCMV resulted in significant morbidity and mortality. Disease induced in the transgenic mice was associated with an increase in the number of CD8 § T lymphocytes within the brain parenchyma, an increased rate of clearance of infectious virus from infected neurons, and an increased permeability of the blood-brain barrier that continued for several months after the adoptive transfer of CTL and after the virus was cleared from infected neurons. Although virus was cleared from Db-expressing neurons by 15 d after adoptive transfer, no obvious lysis of neuronal cells was observed.
Our in vitro findings in transgenic primary embryonic neurons confirm and extend previous results obtained in OBL-21 neuronal cells (14, 17) . In those studies it was shown that OBL-21 cells were unable to present viral antigen to CTL because of a paucity of class I MHC on the OBL-21 cell surface. Molecular complementation with a retrovirally expressed class I MHC molecule made infected OBL-21 cells recognizable and lysable by antiviral CTL. Although OBL-21 cells share many characteristics with neuronal cells (e.g., expression ofneurofilaments, NSE, and voltage-dependent potassium channels; 22), they, unlike primary neurons, are dividing, transformed cells that grow in the presence of serum.
Expressing D b MHC class I proteins in neuronal cells via transgenic technology and panning with mAb to D b in the current study allowed the in vitro analysis of primary neuronal cell-virus-CTL interactions. As these primary neurons do not divide in culture and are grown in the absence of serum, they resemble differentiated neurons in the intact CNS more closely than OBL-21 cells. When transgenic Db-expressing primary neurons were pulsed with viral peptide or infected with virus (Rail, G., and M. B. A. Oldstone, unpublished results) and challenged with MHCmatched antiviral CTL, they were recognized and lysed, whereas primary neurons from nontransgenic mice under similar conditions were not. Thus, expression of a class I MHC molecule on primary neurons in vitro was sufficient to result in lysis by appropriate CTL.
Interestingly, we did not find evidence of CTL-mediated lysis of neurons in brains of transgenic mice, despite the presence of intraparenchymal CTL and rapid viral clearance from the transgenic CNS. However, it should be noted that this study was not designed to accurately quantitate neuronal counts and that a subtle dropout of neurons may have occurred. Nevertheless, neurons of the hippocampus and Purkinje cell layer of the cerebellum are uniformly infected by LCMV in vivo (41, 42 ); yet at no time after adoptive transfer, in no animal, regardless of health, were morphological changes consistent with cell lysis observed in these regions. Thus, while transgenic neurons expressing the correct viral peptide bound to a transgenic MHC molecule were suitable CTL targets in vitro, such neurons did not appear to be effectively lysed in vivo. This observation may be due to a restricted number of CD8 § CTL within the brain, which limits the cytotoxic effect of these cells. We believe this possibility is unlikely, however, given the rapid rate of viral clearance and blood-brain barrier damage within transgenic brains.
Alternatively, one might consider that, while these neurons express the transgene in vitro, they may not in vivo, as no direct evidence (e.g., immunohistochemical identification of the transgene product in brain sections) is provided. We feel that our inability to detect the class l molecule in brain sections was due to technical problems regarding the difficulty of immunostaining within the brain, coupled with the lack of a suitable, high-affinity antibody, and not due to the absence of expression in vivo. The adoptive transfer experiments provide strong evidence for functional protein expression in vivo: three groups of mice (NSE-D b, NSE-APP, and nontransgenic littermates), two lines of the NSE-D b mice (lines 9 and 11), and two different immune lymphocyte haplotypes (b and s) were used to demonstrate a selective effect of H-2 b antiviral lymphocytes on virally infected H-2 b transgenic neuronal targets. Because only the combination of mice expressing the D b molecule with MHC-matched H-2 b immune lymphocytes resulted in pathological conditions (increased intraparenchymal CTL, increased blood-brain barrier permeability, prolonged sickness), functional expression of the class I MHC transgene in neurons is the most plausible explanation for these data.
How these CTL exert their virucidal, but not cytocidal, effects in vivo is not known. It is conceivable that factors released from neurons or glial cells interfere with lytic CTL-neuronal interactions contributing to the relatively immunosuppressive/immune-privileged microenvironment of the CNS, and that such factors interfere with the CTLmediated cytolysis of vitally infected neurons. Isolation of After adoptive transfer of MHC-restricted virus-specific CTL into mice whose neurons contain virus but lack expression of MHC class I molecules, clearance occurs by 60-120 d (41) . Interestingly, in the model reported here, clearance occurs much earlier, by day 15 (Fig. 7) . In both instances, clearance of virus from neurons occurs in the absence oflysis of these cells, suggesting that intraparenchyreal cytokine production may also participate in the clearance of infectious virus from transgenic brains. Inhibition of viral synthesis in the absence of cell death has been documented in the CTL response to hepatitis B virus infection of hepatocytes (47) (48) (49) and in HIV (50) . In these systems, inflammatory cytokines such as IFN-~/ and TNF-ci can down-regulate viral expression without concomitant cell death.
The stability of the blood-brain barrier is critical to the exclusion of potentially neurotoxic or cytolytic bloodborne molecules (such as cytokines) from the CNS parenchyma as well as to the maintenance of an appropriate homeostatic osmotic balance within the brain (51) . While rapid alterations in the permeability of the blood-brain barrier may result in edema and death (52, 53) , slower changes in permeability need not be life threatening but may lead to more chronic neurologic symptoms (54) . In agreement with this concept, we observed a significant increase in animal sickness and death at early times after adoptive transfer, with continued sickness of surviving mice throughout the 150-d observation period.
Several CNS diseases have been associated with transient or permanent changes in blood-brain barrier permeability, including those associated with CNS infection (54-58), demyelinating diseases (59) , and tumors (60). Our study, in which abnormal permeability of the blood-brain barrier and clinical illness were detected long after virus had been cleared from the mice (Fig. 7) , indicates that viral infections and CTL-CNS interactions may induce blood-brain barrier disruptions and neurologic disease by a "hit-and-run" mechanism, triggering a cascade of pathogenic events that proceeds in the absence of continual viral stimulation.
